LMNGF News and Press, BioVaxys Technology From 02/02/21

Vancouver, BC – February 2, 2021 — BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTC:LMNGF) (“BioVaxys” or “Company”) is pleased to announce that its Covid-19 vaccine candidate, BVX-0320, elicits a neutralizing antibody response against SARS-...

Vancouver, British Columbia--(Newsfile Corp. - February 1, 2021) - BioVaxys Technology Corp . (CSE: BIOV) (" BioVaxys " or the " Company "), is pleased to announce a non-brokered private placement (the " Private Placement ") consisting of 4,313,725 units (" Units ") at a price of $0.255 per U...

Palm Beach, FL – January 28, 2021 – According to the National Institutes of Health (NIH), the tide in the global fight against COVID-19, the disease caused by the SARS-CoV-2 virus, may soon begin to turn. Last month, three pharmaceutical companies announced promising results f...

Covid-T™ Clinical Development Program Initiated Regulatory Advisory Group Engaged Canada NewsWire VANCOUVER, BC , Jan. 28, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ( "BioVaxys" or "Company") is pleased to announce tha...

BioVaxys ([[LMNGF]] +34.4%) has commenced the clinical development program for BVX-0918A, its haptenized tumor antigen vaccine for ovarian cancer. It plans to seek a compassionate use approval in the European Union for Stage III & Stage IV ovarian cancer, followed by submission of an...

Palm Beach, FL – January 25, 2021 Ovarian cancer is one of the most deadly gynecologic malignancy across the globe, but new treatments are gaining increased efficacy while displaying reduced toxicity. Clinical trials abound. Immunotherapy using immune-checkpoint modulators has been r...

BioVaxys Announces Initiation of Cancer Vaccine EU Clinical Program, Completion of BVX-0320 Preclinical Program PR Newswire VANCOUVER, BC , Jan. 25, 2021 /PRNewswire/ -- Features Observation Of Neutralizing Antibodies To SARS-CoV-2 Advan...

Palm Beach, FL – December 21, 2020 – Since the global outbreak that triggered the pandemic, scientists around the world have been working on potential treatments and vaccines for the new coronavirus disease known as COVID-19… and they have been making progress at a rapi...

BioVaxys Vaccine Platform Stimulates Robust T-cell Response Against Viral Antigens BVX-0320 ACTIVATES IMMUNE SYSTEM MEMORY 'HELPER ' CD4+ AND KILLER CD8+ T-CELLS AGAINST SARS-COV-2 POTENTIAL FOR LONGER-TERM VIRAL PROTECTION PR Newswire VANCOUVER, Britis...

Vancouver, British Columbia--(Newsfile Corp. - December 10, 2020) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ( "BioVaxys" or "the Company") is pleased to announce that its submission of Form 211 to FINRA has been cleared and the Company's shares now qualify for trading in the United S...